Wedbush Predicts AnaptysBio’s Q1 Earnings (NASDAQ:ANAB)

AnaptysBio, Inc. (NASDAQ:ANAB) – Equities researchers at Wedbush increased their Q1 2025 earnings estimates for shares of AnaptysBio in a research note issued on Monday, February 3rd. Wedbush analyst D. Nierengarten now anticipates that the biotechnology company will earn ($0.44) per share for the quarter, up from their prior forecast of ($0.96). Wedbush has a “Outperform” rating and a $40.00 price objective on the stock. The consensus estimate for AnaptysBio’s current full-year earnings is ($6.08) per share. Wedbush also issued estimates for AnaptysBio’s Q2 2025 earnings at ($0.85) EPS, Q3 2025 earnings at ($0.87) EPS, Q4 2025 earnings at ($0.89) EPS, FY2025 earnings at ($3.05) EPS, FY2026 earnings at ($3.75) EPS, FY2027 earnings at ($4.13) EPS and FY2028 earnings at ($4.77) EPS.

A number of other research analysts also recently issued reports on the stock. JPMorgan Chase & Co. cut their price objective on shares of AnaptysBio from $66.00 to $36.00 and set an “overweight” rating on the stock in a research report on Thursday, December 19th. Wolfe Research started coverage on AnaptysBio in a research report on Tuesday. They set an “outperform” rating and a $25.00 price target on the stock. UBS Group increased their price objective on AnaptysBio from $23.00 to $33.00 and gave the company a “neutral” rating in a report on Wednesday, October 30th. HC Wainwright restated a “neutral” rating and set a $19.00 target price on shares of AnaptysBio in a research note on Tuesday. Finally, BTIG Research cut AnaptysBio from a “buy” rating to a “neutral” rating in a research note on Monday, December 2nd. Four investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $40.08.

AnaptysBio Stock Down 0.9 %

AnaptysBio stock opened at $16.51 on Wednesday. AnaptysBio has a twelve month low of $12.51 and a twelve month high of $41.31. The business has a fifty day moving average of $17.23 and a two-hundred day moving average of $26.89. The firm has a market cap of $502.40 million and a P/E ratio of -2.72.

AnaptysBio (NASDAQ:ANAB) last released its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($1.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.72) by $0.58. AnaptysBio had a negative net margin of 289.75% and a negative return on equity of 287.94%. The company had revenue of $30.02 million during the quarter, compared to analyst estimates of $7.92 million.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in ANAB. Y Intercept Hong Kong Ltd acquired a new position in shares of AnaptysBio during the 4th quarter worth about $311,000. Rhumbline Advisers raised its holdings in shares of AnaptysBio by 3.8% during the fourth quarter. Rhumbline Advisers now owns 30,077 shares of the biotechnology company’s stock valued at $398,000 after acquiring an additional 1,111 shares during the last quarter. Jennison Associates LLC boosted its stake in shares of AnaptysBio by 1.6% in the fourth quarter. Jennison Associates LLC now owns 269,131 shares of the biotechnology company’s stock worth $3,563,000 after acquiring an additional 4,242 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its holdings in AnaptysBio by 11.1% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,452 shares of the biotechnology company’s stock valued at $85,000 after purchasing an additional 644 shares in the last quarter. Finally, SG Americas Securities LLC boosted its stake in AnaptysBio by 35.0% during the 4th quarter. SG Americas Securities LLC now owns 16,307 shares of the biotechnology company’s stock worth $216,000 after purchasing an additional 4,231 shares during the last quarter.

Insider Buying and Selling at AnaptysBio

In other AnaptysBio news, Director Ecor1 Capital, Llc purchased 65,184 shares of the business’s stock in a transaction that occurred on Monday, December 30th. The stock was purchased at an average price of $12.92 per share, for a total transaction of $842,177.28. Following the purchase, the director now directly owns 7,860,180 shares in the company, valued at approximately $101,553,525.60. This trade represents a 0.84 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 33.70% of the stock is currently owned by corporate insiders.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.